GLP-1 Australia: The Complete 2026 Guide
Key Takeaways
Every GLP-1 medication available in Australia in 2026 — how they work, what each costs, who is eligible, and how to access treatment. The complete guide.
GLP-1 medications are the biggest shift in Australian weight management in a generation — and this is the complete guide to GLP-1 in Australia in 2026. Below: how GLP-1s actually work in plain English, every medication available in Australia and what each costs, who is eligible, what results and side effects to expect, and exactly how to get assessed. Dedicated deep-dive guides are linked throughout.
What Is a GLP-1 Receptor Agonist? The Plain-English Version
GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut produces naturally — primarily in specialised cells in the small intestine and colon — in response to eating. When you eat a meal, GLP-1 is released into your bloodstream and does several things simultaneously: it signals to your brain that you're full, slows the rate at which your stomach empties food into the intestine, stimulates your pancreas to release insulin in proportion to blood sugar levels, and suppresses glucagon (a hormone that would otherwise raise blood sugar).
GLP-1 receptor agonists (GLP-1 RAs) are medications that mimic this hormone. By providing a sustained, pharmacological-level activation of GLP-1 receptors, they amplify all of these effects — producing a sustained reduction in appetite, slower gastric emptying, and improved blood sugar regulation. For people with obesity or type 2 diabetes, this has proven transformative.
Which GLP-1 Medications Are Available in Australia?
Several GLP-1 receptor agonists are registered by the TGA and available in Australia in 2026:
- Ozempic (semaglutide, 0.5–2mg/week) — TGA-registered for type 2 diabetes; widely prescribed off-label for weight management
- Wegovy (semaglutide 2.4mg/week) — TGA-registered specifically for chronic weight management in adults
- Rybelsus (oral semaglutide) — TGA-registered for type 2 diabetes; an oral tablet form of semaglutide (less commonly used for weight loss)
- Victoza/Saxenda (liraglutide) — older GLP-1 medications; Saxenda is registered for weight management but has largely been superseded by semaglutide and tirzepatide
- Trulicity (dulaglutide) — registered for type 2 diabetes; less commonly used for weight management
Note: Mounjaro (tirzepatide) is also available in Australia and is technically a dual GIP/GLP-1 agonist rather than a pure GLP-1 agonist — it is covered separately in our Mounjaro guide.
How Do GLP-1 Medications Cause Weight Loss?
The weight loss mechanisms of GLP-1 receptor agonists are multiple and synergistic:
1. Central Appetite Suppression
GLP-1 receptors are present in areas of the brain that regulate hunger and satiety — particularly the hypothalamus and brainstem. Activation of these receptors reduces the drive to eat. Patients consistently report that food becomes less appealing, portion sizes naturally decrease, and urges to snack between meals diminish.
2. Delayed Gastric Emptying
GLP-1 slows the movement of food from the stomach into the small intestine. This prolongs feelings of fullness after meals, reducing total caloric intake even without deliberate calorie counting.
Want to find out which GLP-1 is right for you?
Our GPs can compare your options and assess your suitability via bulk billed telehealth. No referral required.
3. Insulin-Glucagon Balance
By stimulating insulin release and suppressing glucagon in response to meals, GLP-1 agonists improve blood sugar regulation. This reduces the blood sugar spikes and crashes that can drive hunger and cravings.
4. Possible Effects on Food Reward
Emerging research suggests GLP-1 agonists may reduce the dopamine-mediated reward associated with high-calorie, high-fat foods — making those foods feel less compulsive. This is an area of active research.
How Effective Are They? What the Evidence Shows
The clinical trial data for GLP-1 medications is among the strongest ever produced for a non-surgical weight loss intervention:
- Ozempic (semaglutide 1–2mg): Mean weight loss of approximately 10–12% of body weight over 40–68 weeks in SUSTAIN trials
- Wegovy (semaglutide 2.4mg): Mean weight loss of 15–17% of body weight over 68 weeks in STEP trials
- Mounjaro (tirzepatide 15mg): Mean weight loss of 20–22% of body weight over 72 weeks in SURMOUNT trials
For context, older weight loss medications typically produced 5–8% weight loss. Lifestyle intervention alone typically produces 3–5% sustained weight loss in trial conditions. The GLP-1 class represents a step-change in pharmacological effectiveness.
Are GLP-1 Medications Safe?
GLP-1 medications have an established and well-characterised safety profile, having been used in clinical practice for over a decade (liraglutide was first approved internationally in 2010). The key safety points:
- Gastrointestinal effects are common but usually manageable and improve over time. Nausea, vomiting, diarrhoea, and constipation are the most frequently reported.
- Pancreatitis risk is real but rare. Patients with a history of pancreatitis should discuss this with their GP before starting.
- Thyroid C-cell tumour risk was identified in rodent studies at high doses; human relevance is uncertain but patients with personal or family history of medullary thyroid carcinoma or MEN2 should not use these medications.
- Hypoglycaemia risk is low in non-diabetic patients — GLP-1 agonists only stimulate insulin release in response to elevated blood glucose, so dangerous low blood sugar is uncommon without concurrent insulin or sulfonylurea use.
Who Should Not Use GLP-1 Medications?
Contraindications include:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2 (MEN2)
- History of pancreatitis (relative contraindication — discuss with your GP)
- Pregnancy or breastfeeding
- Severe gastrointestinal disease
How Are GLP-1 Medications Administered?
Most GLP-1 medications used for weight loss in Australia are administered via subcutaneous injection once weekly. This is simpler than it sounds:
- Pre-filled auto-injector pens are used — no drawing up of medication required
- Injection is typically into the abdomen, outer thigh, or upper arm
- The needle is very fine and short — most patients find it virtually painless
- The injection takes seconds
The exception is Rybelsus (oral semaglutide), taken as a daily tablet — though this form is less commonly used for weight management.
How Do You Access GLP-1 Medications in Australia?
You need a prescription from an Australian-registered GP. No specialist referral is required. The pathway:
- Consult a GP (telehealth or in-person)
- Undergo a clinical assessment — health history, BMI, comorbidities, contraindications
- Receive a prescription if clinically appropriate
- Fill the prescription at an Australian pharmacy
Weight Loss GP Australia offers bulk billed telehealth consultations for eligible patients — meaning the GP appointment has no out-of-pocket cost. Join our waitlist to be notified when appointments open in your state.
Ready to speak with an Australian GP about weight loss?
Request an appointment with Weight Loss GP Australia — bulk billed through Medicare. No referral required.
Book a Consultation